<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18797468</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1827</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>British journal of cancer</Title><ISOAbbreviation>Br J Cancer</ISOAbbreviation></Journal><ArticleTitle>NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life.</ArticleTitle><Pagination><MedlinePgn>1226-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/sj.bjc.6604674</ELocationID><Abstract><AbstractText>The NEAT trial reported considerable benefit for ECMF (epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil) of 28% for relapse-free survival (RFS) and 30% for overall survival (OS), when compared with classical CMF in early breast cancer. To assess tolerability, toxicity, dose intensity and quality of life (QoL) analyses were undertaken. All 2021 eligible patients had common toxicity criteria (CTC), delivered chemotherapy and supportive treatments details and long-term morbidities recorded. The QoL substudy used multiple validated measures. ECMF produced low CTC scores, although higher than CMF for nausea, vomiting, alopecia, constipation, stomatitis (P&lt;0.001), infection (P=0.001) and fatigue (P=0.03). Supportive treatments required, however, were similar across randomised treatments. On-treatment deaths were more common with CMF (13) than ECMF(5). Optimal course-delivered dose intensity (CDDI &gt; or =85%) was received more often by ECMF patients (83 vs 76%: P=0.0002), and was associated with better RFS (P=0.0006). QoL over 2 years was equivalent across treatments, despite minimally worse side effects for ECMF during treatment. ECMF benefit spanned all levels of toxicity, CDDI and QoL. There are no reported acute myeloid leukaemias or cardiac dysfunctions. ECMF is tolerable, deliverable, and significantly more effective than CMF, with no serious long-term toxicity or QoL detriment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Earl</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Oncology Centre, Addenbrookes Hospital, University of Cambridge, Cambridge CB2 0QQ, UK. hme22@cam.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiller</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Bathers</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Stanley</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Grieve</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>R K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Fernando</LastName><ForeName>I N</ForeName><Initials>IN</Initials></Author><Author ValidYN="Y"><LastName>Brunt</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>McAdam</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rea</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Spooner</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Poole</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><CollectiveName>NEAT Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Cancer</MedlineTA><NlmUniqueID>0370635</NlmUniqueID><ISSNLinking>0007-0920</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3Z8479ZZ5X</RegistryNumber><NameOfSubstance UI="D015251">Epirubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C044626">CMF protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015251" MajorTopicYN="N">Epirubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18797468</ArticleId><ArticleId IdType="pii">6604674</ArticleId><ArticleId IdType="doi">10.1038/sj.bjc.6604674</ArticleId><ArticleId IdType="pmc">PMC2570521</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JAMA. 1995 Feb 15;273(7):542-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7837388</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1984 Nov;2(11):1281-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6387060</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Nov 2;355(18):1851-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17079759</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 1977 Jan;35(1):1-39</Citation><ArticleIdList><ArticleId IdType="pubmed">831755</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Apr 6;332(14):901-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7877646</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2000 Oct 15;19(19):2657-74</Citation><ArticleIdList><ArticleId IdType="pubmed">10986540</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1996 Oct;14(10):2756-68</Citation><ArticleIdList><ArticleId IdType="pubmed">8874337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1992 Jan 11;339(8785):71-85</Citation><ArticleIdList><ArticleId IdType="pubmed">1345869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1998 Sep 19;352(9132):930-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9752815</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1984 Dec;40(4):1079-87</Citation><ArticleIdList><ArticleId IdType="pubmed">6534410</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 1993 Mar 3;85(5):365-76</Citation><ArticleIdList><ArticleId IdType="pubmed">8433390</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>

